摘要
Abstract
Objective To observe the clinical efficacy and safety of entecavir dispersible tablets in the treatment of HBeAg negative compensated patients with chronic hepatitis B.Methods HBeAg negative compensated patients with chronicviral hepatitis type B (CHB)from January 2013 to May 2015 were divided into control group with 42 cases(low viral load group,HBV DNA ＜ 7.00 log10 U · mL-1) and treatment group with 53 cases(high viral load group,HBV DNA ≥7.00 log10 U · mL-1).Two groups received entecavir with 0.5 mg,qd,fasting oral for 48 weeks.Clinical efficiency and adverse drugs reaction (ADR)were investigated after treatment for 48 weeks.The serum HBV DNA,procollagen type Ⅲ (PC Ⅲ)were determined by radioimmunoassay.The alanine aminotransferase (ALT) levels was determined by biochemistry analyzer.Results After treatment for 48 weeks,the total effective rate in treatment group and the control group were 83.02％ and 85.71％,and the difference was not statistically significant(P ＞0.05).After treatment for 12 weeks,serum levels of HBV DNA,PCⅢ and ALT in treatment group and control group were (4.92±0.78)log10 U · mL-1,(162.34 ±13.28)μg· L-1,(95.31 ± 12.19)U · L-1 and(3.89 ±0.75)log10 U · mL-1,(140.56 ± 10.42) μg · L-1,(79.62 ± 11.91) U · L-1,the differences were statistically significant (P ＜ 0.05).After treatment for 24 and 48 weeks,the difference of the factors between two groups were not statistically significant(P ＞0.05).The incidence of ADR in treatment group and control group were 7.55％ and 7.14％,the differences were not statistically significant(P ＞ 0.05).Conclusion Entecavir dispersible tablets can reduce serum HBV DNA levels,and relieve liver fibrosis degree of HBeAg-negative compensated patients with chronic hepatitis B;but there was no significant difference in the long-term effect of the patients with different viral load after 24 weeks and it is safe.关键词
恩替卡韦分散片/乙型病毒性肝炎E抗原/慢性乙型病毒性肝炎/安全性Key words
entecavir dispersible tablets/HBeAg/chronic viral hepatitis B/safety分类
医药卫生
